• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.基于本地数据的减量预防方案可提供近乎最佳的呼吸道合胞病毒防护。
Clin Infect Dis. 2015 Aug 15;61(4):506-14. doi: 10.1093/cid/civ331. Epub 2015 Apr 22.
2
Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.帕利珠单抗注射方案抗呼吸道合胞病毒感染的疗效及优化
JAMA Pediatr. 2015 Apr;169(4):341-8. doi: 10.1001/jamapediatrics.2014.3804.
3
Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.在一家管理式医疗组织中,帕利珠单抗预防呼吸道合胞病毒感染的预先授权结果描述。
J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22. doi: 10.18553/jmcp.2010.16.1.15.
4
Editorial Commentary: Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?编者按:减量预防方案能否提供足够的呼吸道合胞病毒感染防护?
Clin Infect Dis. 2015 Aug 15;61(4):515-6. doi: 10.1093/cid/civ336. Epub 2015 Apr 22.
5
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.英国婴儿人群使用帕利珠单抗(Synagis)预防呼吸道合胞病毒的成本效果更新分析。
J Med Econ. 2020 Dec;23(12):1640-1652. doi: 10.1080/13696998.2020.1836923. Epub 2020 Oct 27.
6
Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.2014 年美国儿科学会推荐意见的影响,以及意大利药品管理局因此对帕利珠单抗预防治疗的有限财政覆盖,对 2016-2017 年流行季早产儿中与 RSV 相关的住院治疗的影响:对七项意大利报告的系统评价。
Ital J Pediatr. 2019 Nov 9;45(1):139. doi: 10.1186/s13052-019-0736-5.
7
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.帕利珠单抗是一种人源化呼吸道合胞病毒单克隆抗体,可降低高危婴儿因呼吸道合胞病毒感染而住院的几率。IMpact-RSV研究小组。
Pediatrics. 1998 Sep;102(3 Pt 1):531-7.
8
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.使用帕利珠单抗对儿童进行呼吸道合胞病毒(RSV)免疫预防:一项系统评价与经济学评估
Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. doi: 10.3310/hta12360.
9
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.帕利珠单抗预防高危婴儿和幼儿呼吸道合胞病毒(RSV)毛细支气管炎的免疫预防作用:亚组分析的系统评价和额外的经济建模。
Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050.
10
Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.在医疗补助计划人群中,帕利珠单抗部分预防与呼吸道合胞病毒导致的住院风险增加:一项回顾性队列分析
BMC Pediatr. 2014 Oct 13;14:261. doi: 10.1186/1471-2431-14-261.

引用本文的文献

1
Wastewater-based surveillance as a tool for public health action: SARS-CoV-2 and beyond.基于污水的监测作为公共卫生行动的工具:SARS-CoV-2 及其他。
Clin Microbiol Rev. 2024 Mar 14;37(1):e0010322. doi: 10.1128/cmr.00103-22. Epub 2023 Dec 14.
2
Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children.预测疫苗和延长半衰期单克隆抗体预防儿童呼吸道合胞病毒住院的有效性。
NPJ Vaccines. 2022 Oct 27;7(1):127. doi: 10.1038/s41541-022-00550-5.
3
Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.最大限度发挥预防策略对婴幼儿呼吸道合胞病毒(RSV)疾病影响的挑战。
Yale J Biol Med. 2022 Jun 30;95(2):293-300. eCollection 2022 Jun.
4
Relative timing of respiratory syncytial virus epidemics in summer 2021 across the United States was similar to a typical winter season.2021 年夏季美国呼吸道合胞病毒流行的相对时间与典型的冬季季节相似。
Influenza Other Respir Viruses. 2022 Jul;16(4):617-620. doi: 10.1111/irv.12965. Epub 2022 Feb 8.
5
Community factors associated with local epidemic timing of respiratory syncytial virus: A spatiotemporal modeling study.与呼吸道合胞病毒局部流行时间相关的社区因素:一项时空建模研究。
Sci Adv. 2021 Jun 23;7(26). doi: 10.1126/sciadv.abd6421. Print 2021 Jun.
6
Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996-2013.1996-2013 年康涅狄格州呼吸道合胞病毒预防措施的评估与优化。
Sci Rep. 2021 May 21;11(1):10684. doi: 10.1038/s41598-021-90107-8.
7
Epidemic dynamics of respiratory syncytial virus in current and future climates.呼吸道合胞病毒在当前和未来气候中的流行动力学。
Nat Commun. 2019 Dec 4;10(1):5512. doi: 10.1038/s41467-019-13562-y.
8
Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis.先天性心脏病患儿采用简化帕利珠单抗方案治疗呼吸道合胞病毒感染的相关结局:一项描述性分析
CMAJ Open. 2019 Feb 18;7(1):E88-E93. doi: 10.9778/cmajo.20180167. Print 2019 Jan-Mar.
9
Timing of respiratory syncytial virus and influenza epidemic activity in five regions of Argentina, 2007-2016.2007-2016 年阿根廷五个地区呼吸道合胞病毒和流感流行活动的时间。
Influenza Other Respir Viruses. 2019 Jan;13(1):10-17. doi: 10.1111/irv.12596. Epub 2018 Nov 20.
10
Local variations in the timing of RSV epidemics.呼吸道合胞病毒流行时间的局部差异。
BMC Infect Dis. 2016 Nov 11;16(1):674. doi: 10.1186/s12879-016-2004-2.

本文引用的文献

1
Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States.美国呼吸道合胞病毒时空动态的环境驱动因素
PLoS Pathog. 2015 Jan 8;11(1):e1004591. doi: 10.1371/journal.ppat.1004591. eCollection 2015 Jan.
2
Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data.呼吸道合胞病毒活动与婴儿肺炎球菌疾病之间的关联:美国住院数据的时间序列分析
PLoS Med. 2015 Jan 6;12(1):e1001776. doi: 10.1371/journal.pmed.1001776. eCollection 2015 Jan.
3
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.呼吸道合胞病毒感染住院风险增加的婴幼儿使用帕利珠单抗预防的更新指南。
Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665.
4
Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study.英国呼吸道合胞病毒细支气管炎住院的危险因素:一项基于人群的出生队列研究。
PLoS One. 2014 Feb 26;9(2):e89186. doi: 10.1371/journal.pone.0089186. eCollection 2014.
5
Respiratory syncytial virus surveillance in the United States, 2007-2012: results from a national surveillance system.2007 - 2012年美国呼吸道合胞病毒监测:来自国家监测系统的结果
Pediatr Infect Dis J. 2014 Jun;33(6):589-94. doi: 10.1097/INF.0000000000000257.
6
Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.小于 24 月龄儿童因呼吸道合胞病毒导致的住院治疗。
Pediatrics. 2013 Aug;132(2):e341-8. doi: 10.1542/peds.2013-0303. Epub 2013 Jul 22.
7
Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children.免疫功能低下儿童呼吸道合胞病毒感染的危险因素和结局。
Pediatr Infect Dis J. 2013 Oct;32(10):1073-6. doi: 10.1097/INF.0b013e31829dff4d.
8
Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review.流感和呼吸道合胞病毒(RSV)季节性活动的纬度变化:全球比较综述。
PLoS One. 2013;8(2):e54445. doi: 10.1371/journal.pone.0054445. Epub 2013 Feb 14.
9
A review of cost-effectiveness of palivizumab for respiratory syncytial virus.帕利珠单抗治疗呼吸道合胞病毒的成本效益评价综述。
Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):553-67. doi: 10.1586/erp.12.45. Epub 2012 Nov 11.
10
Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.美国医疗补助计划覆盖的早产儿人群中帕利珠单抗的成本效益分析。
J Med Econ. 2012;15(5):997-1018. doi: 10.3111/13696998.2012.672942. Epub 2012 Mar 21.

基于本地数据的减量预防方案可提供近乎最佳的呼吸道合胞病毒防护。

Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

作者信息

Weinberger Daniel M, Warren Joshua L, Steiner Claudia A, Charu Vivek, Viboud Cécile, Pitzer Virginia E

机构信息

Department of Epidemiology of Microbial Disease.

Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.

出版信息

Clin Infect Dis. 2015 Aug 15;61(4):506-14. doi: 10.1093/cid/civ331. Epub 2015 Apr 22.

DOI:10.1093/cid/civ331
PMID:25904370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4542596/
Abstract

BACKGROUND

Respiratory syncytial virus (RSV) is a major cause of respiratory infections among young children and can lead to severe disease among some infants. Infants at high risk for severe RSV infection receive monthly injections of a prophylactic monoclonal antibody during the RSV season based on national guidelines. We considered whether a reduced-dose schedule tailored to the local RSV season in the continental United States would provide adequate protection.

METHODS

Hospitalization data for 1942 counties across 38 states from 1997 to 2009 were obtained from the State Inpatient Databases (Agency for Healthcare Research and Quality). We assessed the timing of RSV epidemics at the county and state levels using a 2-stage hierarchical Bayesian change point model. We used a simple summation approach to estimate the fraction of RSV cases that occur during the window of protection provided by initiating RSV prophylaxis during different weeks of the year.

RESULTS

The timing of RSV epidemic onset varied significantly at the local level. Nevertheless, the national recommendations for initiation of prophylaxis provided near-optimal coverage of the RSV season in most of the continental United States. Reducing from 5 to 4 monthly doses (with a later initiation) provides near-optimal coverage (<5% decrease in coverage) in most settings. Earlier optimal dates for initiating 4 doses of prophylaxis were associated with being farther south and east, higher population density, and having a higher percentage of the population that was black or Hispanic.

CONCLUSIONS

A 4-dose schedule of prophylactic injections timed with local RSV epidemics could provide protection comparable to 5 doses and could be considered as a way to improve the cost-effectiveness of prophylaxis.

摘要

背景

呼吸道合胞病毒(RSV)是幼儿呼吸道感染的主要病因,可导致部分婴儿出现严重疾病。根据国家指南,重度RSV感染高危婴儿在RSV流行季节每月注射一剂预防性单克隆抗体。我们探讨了根据美国大陆当地RSV流行季节量身定制的减少剂量方案是否能提供足够的保护。

方法

从州住院数据库(医疗保健研究与质量局)获取了1997年至2009年38个州1942个县的住院数据。我们使用两阶段分层贝叶斯变化点模型评估了县和州层面RSV流行的时间。我们采用简单求和方法来估计在一年中不同周开始进行RSV预防所提供的保护期内发生的RSV病例所占比例。

结果

RSV流行开始的时间在地方层面差异显著。尽管如此,全国性的预防起始建议在美国大陆大部分地区提供了接近最佳的RSV流行季节覆盖范围。将每月剂量从5剂减至4剂(起始时间稍晚)在大多数情况下提供了接近最佳的覆盖范围(覆盖范围减少<5%)。开始4剂预防的较早最佳日期与更偏南和偏东、人口密度较高以及黑人或西班牙裔人口比例较高有关。

结论

根据当地RSV流行情况安排的4剂预防性注射方案可提供与5剂相当的保护,可被视为提高预防成本效益的一种方式。